Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company also develops SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat central nervous system, as well as has a research pipeline of investigational psychedelic-based compounds. It has a strategic partnership agreement with Segal Trials to support PARADIGM, a multinational pivotal phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder. The company is headquartered in Toronto, Canada.
तुलना करने के लिए मीट्रिक्स | HELP | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधHELPपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −2.3x | −2.4x | −0.5x | |
PEG अनुपात | 0.24 | 0.01 | 0.00 | |
क़ीमत/बुक | 1.0x | 2.9x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 20.8x | 3.2x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 146.6% | 44.7% | |
उचित मूल्य अपसाइड | अनलॉक करें | −2.7% | 5.7% | अनलॉक करें |